Non-alcoholic steatohepatitis: What is it, and why is it important in the Asia-Pacific region?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 2, 2003, Pages 124-138

  Farrell, Geoffrey C ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Asia Pacific region; Cirrhosis; Diagnosis; Insulin resistance; Lifestyle changes; Metabolic liver disease; Non alcoholic steatohepatitis; Prevention; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BETAINE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROBUCOL; ROSIGLITAZONE; S ADENOSYLMETHIONINE; SILYMARIN; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; URSODEOXYCHOLIC ACID;

AGE; ALCOHOL CONSUMPTION; ANTHROPOMETRY; ASIA; CALORIC INTAKE; CAUSE OF DEATH; CHRONIC LIVER DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIET; DISEASE COURSE; DRUG FATALITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; EXERCISE; FAT INTAKE; FATTY LIVER; FIBROGENESIS; GENETIC PREDISPOSITION; HEALTH BEHAVIOR; HEPATITIS; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; JAPAN; LIFESTYLE; LIPID BLOOD LEVEL; LIVER BIOPSY; LIVER CANCER; LIVER CIRRHOSIS; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER PROTECTION; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; RISK FACTOR; URBANIZATION; VITAMIN SUPPLEMENTATION;

EID: 0037299949     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.02989.x     Document Type: Conference Paper

References (94)

1. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-8.
2. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-74.
3. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Sem. Liv. Dis. 2001; 21: 27-41.
4. Seth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann. Intern. Med. 1997; 126: 137-45.
5. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
6. Fiatarone JR, Coverdale SA, Batey RG, Farrell GC. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. J. Gastroenterol. Hepatol. 1991; 6: 585-90.
7. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 746-52.
8. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 16: 1221-31.
9. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case study. Hepatology 2000; 32: 689-92.
10. Ratzui V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
11. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
12. Caldwell SH, Oelsner DH, Iezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
13. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19.
14. Hui JM, Chitturi S, Farrell GC, George J. The long-term outcome of cirrhosis related to non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2002; 17 (Suppl.): A154.
15. Hasan I, Gani RA, Machmud R et al. Prevalence and risk factors for nonalcoholic fatty liver in Indonesia. J. Gastroenterol, Hepatol. 2002; 17 (Suppl,): A30.
16. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
17. Marceau P, Biron S, Hould FS et al. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab. 1999; 84: 1513-17.
18. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999; 107: 450-5.
19. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002; 35: 367-72.
20. Marchesini G, Forlani G. NASH: From liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002; 35: 497-9.
21. Garcia-Monzon C, Martin-Perez E, Iacono OL et al. Characterisation of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J. Hepatol. 2000; 33: 716-24.
22. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates with body mass index and steatosis. Hepatology 1999; 29: 1215-19.
23. Hwang SJ, Luo JC, Chu CW et al. Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation. J. Gastroenterol. Hepatol. 2001; 16: 190-5.
24. Hui JM, Kench J, Farrell GC et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J. Gastroenterol. Hepatol. 2002; 17: 873-81.
25. Naveau S, Giraud V, Borotto E et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-11.
26. Shimada M, Hashimoto E, Taniai M et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002; 37: 154-60.
27. Ratzui V, Bonhay L, Di Martino V et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.
28. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
29. Bacon BR, Frahvash MJ, Janney CG et al. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
30. Ludwig J, McGill DB, Lindor KD. Nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 1997; 12: 398-403.
31. James OFW, Day CP, Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J. Hepatol. 1998; 29: 495-501.
32. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
33. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
34. Daniel M, Rowley KG, McDermott R, O'Dea K. Diabetes and impaired glucose tolerance in Aboriginal Australians: prevalence and risk. Diabetes Res. Clin. Pract. 2002; 57: 23-33.
35. Khebir BV, Osman A, Khalid BA. Changing prevalence of diabetes mellitus amongst rural Malays in Kuala Selangor over a 10-year period. Med. J. Malaysia 1996; 51: 41-7.
36. Mafauzy M, Mokhtar N, Mahamad WB, Musalmah M. Diabetes mellitus and associated cardiovascular risk factors in north-east Malaysia. Asia Pac. J. Public Health 1999; 11: 16-19.
37. Chunming C. Fat intake and nutritional status of children in China. Am. J. Clin. Nutr. 2000; 72 (Suppl.): 1368S-72S.
38. Sanguanrungsirikul S, Somboonwong J, Nakhnahup C, Pruksananonda C. Energy expenditure and physical activity of obese and non-obese Thai children. J. Med. Assoc. Thai. 2001; 84 (Suppl. 1): S314-20.
39. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
40. Dudeja V, Misra A, Pandey RM, Devina G, Kumar G, Vikram NK. BMI does not accurately predict overweight in Asian Indians in northern India. Br. J. Nutr. 2001; 86: 105-12.
41. International Obesity Taskforce. The Asia-Pacific Perspective: Redefining obesity and its treatment. Sydney: Health Communications Australia, 2000; 1-56.
42. Hsieh SD, Yoshinaga H, Muto T et al. Health risks among Japanese men with moderate body mass index. Int. J. Obes. Relat. Metab. Disord. 2000; 24: 358-62.
43. Akahoshi M, Amasaki Y, Soda M et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens. Res. 2001; 24: 337-43.
44. Rocchini AP. Childhood obesity and a diabetes epidemic. N. Engl. J. Med. 2002; 346: 854-5.
45. Struben VMD, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am. J. Med. 2000; 108: 9-13.
46. Oshibuchi M, Nishi F, Sato M et al. Frequency of abnormalities detected by abdominal ultrasound among Japanese adults. J. Gastroenterol. Hepatol. 1991; 6: 165-8.
47. Omagari KH, Kadokawa Y, Masuda J et al. Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J. Gastroenterol. Hepatol. 2002; 17: 1089-105.
48. Tobe K, Ogura T, Tsukamoto C et al. Relationship between serum leptin and fatty liver in Japanese male adolescent University students. Am. J. Gastroenterol. 1999; 94: 3328-35.
49. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 1997; 27: 103-7.
50. Seki S, Kitada T, Yamada T et al. In situ determination of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 2002; 37: 56-62.
51. Taniguchi A, Nakai Y, Sakai M et al. Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients. Metabolism 2002; 51: 544-8.
52. Rashid M, Roberts E. Nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 2000; 30: 48-53.
53. Manton ND, Lipsett J, Moore DJ et al. Non-alcoholic steatohepatitis in children and adolescents. Med. J. Aust. 2000; 173: 476-9.
54. George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-18.
55. Bonkovsky HL, Jawaid Q, Tortorelli K et al. Nonalcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J. Hepatol. 1999; 31: 421-9.
56. Younossi ZM, Gramlich T, Bacon BR et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-50
57. Chitturi C, Weltman M, Farrell GC et al. HFE mutations, hepatic iron, and fibrosis: Ethnic-specific associations of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-8.
58. Teli MR, James OF, Burr AD et al. The natural history of nonalcoholic fatty liver. Hepatology 1995; 22: 1714-19.
59. de Marco R., Locatelli F, Zoppini G et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756-61.
60. Day CP, James OFW. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998; 114: 842-5.
61. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis V. Mitochondrial dysfunction in steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 282: G193-9.
62. Reddy JK. Nonalcoholic steatosis and steatohepatitis III. Peroxisomal B-oxidation, PPARalpha, and steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2001; 281: G1333-9.
63. Chitturi S, Farrell G, Frost L et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403-9.
64. Mendler MH, Turlin B, Moirand R et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63.
65. Degoul F, Sutton A, Mansouri A. et al. Homozygosity for alanine in the mitochondrial targeting sequence of manganese superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 2001; 120: 1468-74.
66. Macdonald GA, Bridle KR, Ward PJ et al. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J. Gastroentrol. Hepatol. 2001; 16: 599-601.
67. Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J. Hepatol. 1999; 31: 430-4.
68. Cortez-Pinto H, Chatham J, Chacko VP et al. Alteration in liver ATP homeostasis in human non-alcoholic steatosis. A pilot study. JAMA 1999; 282: 1659-40.
69. Fong DG, Nehra V, Lindor KD et al. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000; 32: 3-10.
70. Baffy G, Zhang C-Y, Glickman JN, Lowell BB. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology 2002; 35: 753-61.
71. Angulo P, Lindor D. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001; 120: 1281-5.
72. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
73. Weltman MD, Farrell GC, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
74. Leclercq IA, Farrell GC, Field J et al. Cyp2E1 and cyP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J. Clin. Invest. 2000; 105: 1067-75.
75. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol. 2001; 281: G1135-9.
76. Farrell GC. Is bacterial ash the flash that ignites NASH? Gut 2001; 48: 148-9.
77. Yang SQ, Lin HZ, Mandal AK et al. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001; 34: 694-706.
78. Phung N, Farrell G, Robertson G, George J. Antioxidant therapy with vitamin E ameliorates hepatic fibrosis in MCDD-associated NASH. J. Gasterenterol. Hepatol. 2001; 16 (Suppl.): A52.
79. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. 2002; 37: 206-13.
80. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Sem. Liver Dis. 2002; 22: 137-44.
81. Leclercq IA, Field J, Farrell GC. Leptin-specific mechanism for impaired liver regeneration in ob/ob mice after toxic liver injury. Roles of TNF release and STAT3 regulation. Gastroenterology 2003 (provisionally accepted for publication).
82. Capron J-P, Delamarre J, Dupas J-L et al. Fasting in obesity. Another cause of liver injury with alcoholic hyaline? Dig. Dis. Sci. 1982; 27: 265-8.
83. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-13.
84. Hickman IJ, Clouston AD, Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89-94.
85. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001; 344: 1343-50.
86. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346: 393-403.
87. Farrell GC. Hepatitis C, Other Liver Disorders, and Liver Health. A Practical Guide. Sydney: Maclennan and Petty, 2002; 1-324.
88. Tataranni PA, Bogardus C. Changing habits to delay diabetes. N. Engl. J. Med. 2001; 344: 1390-1.
89. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Sem. Liver Dis. 2001; 21: 81-8.
90. Marchesini G, Brizi M, Bianchi G et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
91. Caldwell SH, Hespendheide EE, Redick JA et al. A pilot study of thiazolidinedione, troglitazone in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2001; 96: 519-25.
92. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr. 2000; 136: 734-8.
93. Abdelmalek M, Angulo P, Jorgensen RA et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 2001; 96: 2711-17.
94. Laurin J, Lindor KD, Crippin JS et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.